GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

117.81 17.65 −13.03%
Market cap
$6.1B
P/E
0.0×
Fwd P/E
−5.7×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — — 6
ROE
(16.83%) (16.07%) (16.09%) (16.12%)
ROA
(14.21%) (13.83%) (13.99%) (14.12%)
ROIC
(21.13%) (21.00%) (20.28%) (20.79%)
Return on Tangible Assets
(71.51%) (44.10%) (46.48%) (44.73%)
Average Days of Receivables
41.90 45.37 47.57 43.64
Free Cash Flow per Share
(9.13) (8.16) (7.19) (6.87)
Free Cash Flow
(329.83) (299.92) (292.33) (296.16)
Other line items

Show all line items

Columns are period end dates